Stocks
Rhythm Pharmaceuticals, Inc.RYTM
NASDAQHealthcareBiotechnology$105.02
Price as of · delayed, not real-time
A commercial-stage biopharmaceutical company focused on treating rare neuroendocrine disorders, with its lead therapy, Imcivree, approved for obesity linked to specific gene variants. The company is expanding its pipeline into earlier-stage metabolic and genetic obesity indications, making it a key name to watch in the rare disease space. Investors track RYTM for its commercial execution and regulatory progress in a niche but growing market.
52W Range: $74.50-$122.20
Congressional Interest in Rhythm Pharmaceuticals, Inc. (RYTM)
No congressional trades have been disclosed for Rhythm Pharmaceuticals, Inc. (RYTM) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading RYTM?
No congressional trades found for this stock.